Humacyte (HUMA) Cash & Equivalents (2020 - 2026)

Humacyte (HUMA) has 7 years of Cash & Equivalents data on file, last reported at $48.5 million in Q1 2026.

• Cash & Equivalents for Q1 2026 came in at $48.5 million, down 22.71% year-over-year; the trailing twelve-month figure through Mar 2026 was $48.5 million (down 22.71% YoY), and the FY2025 annual result was $50.5 million, up 12.37% from the prior year.
• Cash & Equivalents fell to $48.5 million in Q1 2026 per HUMA's latest filing, from $50.5 million in the prior quarter.
• Over five years, Cash & Equivalents peaked at $198.2 million in Q1 2022 and troughed at $19.5 million in Q3 2025.
• A 5-year average of $94.8 million and a median of $93.6 million in 2024 frame the typical range for Cash & Equivalents.
• The sharpest annual moves came in 2022 and 2024: Cash & Equivalents surged 47118.31% in 2022, then plunged 79.4% in 2024.
• A 5-year view of Cash & Equivalents shows it stood at $149.8 million in 2022, then slumped by 46.29% to $80.4 million in 2023, then tumbled by 44.14% to $44.9 million in 2024, then rose by 12.37% to $50.5 million in 2025, then dropped by 3.88% to $48.5 million in 2026.
• Business Quant data shows HUMA's Cash & Equivalents at $48.5 million in Q1 2026, $50.5 million in Q4 2025, and $19.5 million in Q3 2025.